Identifier | Trial design/phase/current status | Rationale | Study group |
---|---|---|---|
NCT02243371 | GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab/phase2/active, not recruiting | Priming of tumor microenvironment and T cells/activation of effector immune system | Previously treated metastatic pancreatic adenocarcinoma |
NCT03153410 | Pilot study of cyclophosphamide, pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in patients with borderline resectable adenocarcinoma of the pancreas/phase 1/recruiting | Depleting/inhibiting negative regulators of immune response and priming of tumor microenvironment | Borderline resectable adenocarcinoma |
NCT03190265 | Study of CRS-207, nivolumab and ipilimumab with or without GVAX pancreas vaccine (with CY) in patients with pancreatic cancer/recruiting | Priming of tumor microenvironment and T cells/activation of effector immune system | Previously treated metastatic pancreatic adenocarcinoma |
NCT03161379 | GVAS pancreas vaccine with cyclophosphamide in combination with nivolumab and SBRT for patients with borderline resectable pancreatic cancer/phase 2/recruiting | Priming of tumor microenvironment and T cells/activation of effector immune system | Borderline resectable pancreatic adenocarcinoma |
NCT02451982 | Neoadjuvant/adjuvant GVAX pancreas vaccine (with CY) With or without nivolumab and urelumab trial for surgically resectable pancreatic cancer/phase1-2/recruiting | Priming of tumor microenvironment and activation of effector immune cells | Surgically resectable pancreatic adenocarcinoma |
NCT02648282 | Study with cyclophosphamide pembrolizumab, GVAX, and SBRT in patients with locally advanced pancreatic cancer/phase2/recruiting | Priming of tumor microenvironment and activation of effector immune cells | Locally advance pancreatic adenocarcinoma |